iRadimed Corp. (NASDAQ:IRMD) shares saw an uptick in trading volume on Wednesday . 172,481 shares were traded during trading, an increase of 128% from the previous session’s volume of 75,536 shares.The stock last traded at $16.96 and had previously closed at $17.86.

A number of research firms have recently issued reports on IRMD. Roth Capital restated a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd. Zacks Investment Research lowered shares of iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 5th.

The company has a market cap of $181.00 million and a PE ratio of 24.37. The firm’s 50-day moving average is $19.93 and its 200-day moving average is $18.32.

iRadimed Corp. (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. During the same quarter in the previous year, the business posted $0.16 EPS. The company earned $9.90 million during the quarter, compared to analyst estimates of $9.60 million. The company’s revenue was up 30.3% compared to the same quarter last year. Equities research analysts expect that iRadimed Corp. will post $0.92 earnings per share for the current year.

In other news, Director Monty K. Allen sold 2,100 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $20.44, for a total value of $42,924.00. Following the transaction, the director now owns 4,375 shares of the company’s stock, valued at approximately $89,425. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Monty K. Allen sold 2,275 shares of the firm’s stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $20.00, for a total transaction of $45,500.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in iRadimed Corp. stock. GSA Capital Partners LLP raised its stake in shares of iRadimed Corp. (NASDAQ:IRMD) by 174.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,203 shares of the company’s stock after buying an additional 31,901 shares during the period. GSA Capital Partners LLP owned 0.45% of iRadimed Corp. worth $1,407,000 at the end of the most recent quarter.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.